FDA: Gout Drug Uloric Increases Risk of Death
FRIDAY, Feb. 22, 2019 -- The gout medicine Uloric (febuxostat) carries a higher risk of death than allopurinol, according to the U.S. Food and Drug Administration.
The agency said its in-depth review of results from a safety clinical trial found...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Allopurinol | Clinical Trials | Food and Drug Administration (FDA) | Gout | Pharmaceuticals